Cargando…

Does Anybody Want an Injectable Rotavirus Vaccine, and Why? Understanding the Public Health Value Proposition of Next-Generation Rotavirus Vaccines

Routine infant immunization with live, oral rotavirus vaccines (LORVs) has had a major impact on severe gastroenteritis disease. Nevertheless, in high morbidity and mortality settings rotavirus remains an important cause of disease, partly attributable to the sub-optimal clinical efficacy of LORVs i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hausdorff, William P., Price, Jessica, Debellut, Frédéric, Mooney, Jessica, Torkelson, Andrew A., Giorgadze, Khatuna, Pecenka, Clint
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880741/
https://www.ncbi.nlm.nih.gov/pubmed/35214608
http://dx.doi.org/10.3390/vaccines10020149
_version_ 1784659294799527936
author Hausdorff, William P.
Price, Jessica
Debellut, Frédéric
Mooney, Jessica
Torkelson, Andrew A.
Giorgadze, Khatuna
Pecenka, Clint
author_facet Hausdorff, William P.
Price, Jessica
Debellut, Frédéric
Mooney, Jessica
Torkelson, Andrew A.
Giorgadze, Khatuna
Pecenka, Clint
author_sort Hausdorff, William P.
collection PubMed
description Routine infant immunization with live, oral rotavirus vaccines (LORVs) has had a major impact on severe gastroenteritis disease. Nevertheless, in high morbidity and mortality settings rotavirus remains an important cause of disease, partly attributable to the sub-optimal clinical efficacy of LORVs in those settings. Regardless of the precise immunological mechanism(s) underlying the diminished efficacy, the introduction of injectable next-generation rotavirus vaccines (iNGRV), currently in clinical development, could offer a potent remedy. In addition to the potential for greater clinical efficacy, precisely how iNGRVs are delivered (multiple doses to young infants; alongside LORVs or as a booster; co-formulated with Diphtheria-Tetanus-Pertussis (DTP)-containing vaccines), their pricing, and their storage and cold chain characteristics could each have major implications on the resultant health outcomes, on cost-effectiveness as well as on product preferences by national stakeholders and healthcare providers. To better understand these implications, we critically assessed whether there is a compelling public health value proposition for iNGRVs based on potential (but still hypothetical) vaccine profiles. Our results suggest that the answer is highly dependent on the specific use cases and potential attributes of such novel vaccines. Notably, co-formulation of iNGRVs with similar or greater efficacy than LORVs with a DTP-containing vaccine, such as DTP-Hib-HepB, scored especially high on potential impact, cost-effectiveness, and strength of preference by national stakeholders and health care providers in lower and middle income countries.
format Online
Article
Text
id pubmed-8880741
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88807412022-02-26 Does Anybody Want an Injectable Rotavirus Vaccine, and Why? Understanding the Public Health Value Proposition of Next-Generation Rotavirus Vaccines Hausdorff, William P. Price, Jessica Debellut, Frédéric Mooney, Jessica Torkelson, Andrew A. Giorgadze, Khatuna Pecenka, Clint Vaccines (Basel) Review Routine infant immunization with live, oral rotavirus vaccines (LORVs) has had a major impact on severe gastroenteritis disease. Nevertheless, in high morbidity and mortality settings rotavirus remains an important cause of disease, partly attributable to the sub-optimal clinical efficacy of LORVs in those settings. Regardless of the precise immunological mechanism(s) underlying the diminished efficacy, the introduction of injectable next-generation rotavirus vaccines (iNGRV), currently in clinical development, could offer a potent remedy. In addition to the potential for greater clinical efficacy, precisely how iNGRVs are delivered (multiple doses to young infants; alongside LORVs or as a booster; co-formulated with Diphtheria-Tetanus-Pertussis (DTP)-containing vaccines), their pricing, and their storage and cold chain characteristics could each have major implications on the resultant health outcomes, on cost-effectiveness as well as on product preferences by national stakeholders and healthcare providers. To better understand these implications, we critically assessed whether there is a compelling public health value proposition for iNGRVs based on potential (but still hypothetical) vaccine profiles. Our results suggest that the answer is highly dependent on the specific use cases and potential attributes of such novel vaccines. Notably, co-formulation of iNGRVs with similar or greater efficacy than LORVs with a DTP-containing vaccine, such as DTP-Hib-HepB, scored especially high on potential impact, cost-effectiveness, and strength of preference by national stakeholders and health care providers in lower and middle income countries. MDPI 2022-01-20 /pmc/articles/PMC8880741/ /pubmed/35214608 http://dx.doi.org/10.3390/vaccines10020149 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hausdorff, William P.
Price, Jessica
Debellut, Frédéric
Mooney, Jessica
Torkelson, Andrew A.
Giorgadze, Khatuna
Pecenka, Clint
Does Anybody Want an Injectable Rotavirus Vaccine, and Why? Understanding the Public Health Value Proposition of Next-Generation Rotavirus Vaccines
title Does Anybody Want an Injectable Rotavirus Vaccine, and Why? Understanding the Public Health Value Proposition of Next-Generation Rotavirus Vaccines
title_full Does Anybody Want an Injectable Rotavirus Vaccine, and Why? Understanding the Public Health Value Proposition of Next-Generation Rotavirus Vaccines
title_fullStr Does Anybody Want an Injectable Rotavirus Vaccine, and Why? Understanding the Public Health Value Proposition of Next-Generation Rotavirus Vaccines
title_full_unstemmed Does Anybody Want an Injectable Rotavirus Vaccine, and Why? Understanding the Public Health Value Proposition of Next-Generation Rotavirus Vaccines
title_short Does Anybody Want an Injectable Rotavirus Vaccine, and Why? Understanding the Public Health Value Proposition of Next-Generation Rotavirus Vaccines
title_sort does anybody want an injectable rotavirus vaccine, and why? understanding the public health value proposition of next-generation rotavirus vaccines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880741/
https://www.ncbi.nlm.nih.gov/pubmed/35214608
http://dx.doi.org/10.3390/vaccines10020149
work_keys_str_mv AT hausdorffwilliamp doesanybodywantaninjectablerotavirusvaccineandwhyunderstandingthepublichealthvaluepropositionofnextgenerationrotavirusvaccines
AT pricejessica doesanybodywantaninjectablerotavirusvaccineandwhyunderstandingthepublichealthvaluepropositionofnextgenerationrotavirusvaccines
AT debellutfrederic doesanybodywantaninjectablerotavirusvaccineandwhyunderstandingthepublichealthvaluepropositionofnextgenerationrotavirusvaccines
AT mooneyjessica doesanybodywantaninjectablerotavirusvaccineandwhyunderstandingthepublichealthvaluepropositionofnextgenerationrotavirusvaccines
AT torkelsonandrewa doesanybodywantaninjectablerotavirusvaccineandwhyunderstandingthepublichealthvaluepropositionofnextgenerationrotavirusvaccines
AT giorgadzekhatuna doesanybodywantaninjectablerotavirusvaccineandwhyunderstandingthepublichealthvaluepropositionofnextgenerationrotavirusvaccines
AT pecenkaclint doesanybodywantaninjectablerotavirusvaccineandwhyunderstandingthepublichealthvaluepropositionofnextgenerationrotavirusvaccines